How Biotech M&A is Redefining the Strategic Landscape episode artwork

EPISODE · Jun 23, 2023 · 25 MIN

How Biotech M&A is Redefining the Strategic Landscape

from Pathfinders in Biopharma

Given current macro and regulatory headwinds, determining the optimal time to sell a biotech company is a multifaceted decision that requires careful consideration of several key factors. Hear from industry veterans Ted Love, Marc de Garidel, and Abbas Kazimi who share their insights on a new era of M&A in a panel moderated by RBC Capital Markets Analysts Dr. Brian Abrahams, Dr. Luca Issi and Dr. Gregory Renza.

Episode metadata supplied by the publisher feed · Published Jun 23, 2023

Embed this episode

NOW PLAYING

How Biotech M&A is Redefining the Strategic Landscape

0:00 25:53

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

No similar episodes found.

No similar podcasts found.

Frequently Asked Questions

How long is this episode of Pathfinders in Biopharma?

This episode is 25 minutes long.

When was this Pathfinders in Biopharma episode published?

This episode was published on June 23, 2023.

Can I download this Pathfinders in Biopharma episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!